Small TP53 mutated subclones discovered on ultra-deep next generation sequencing (NGS) account for 30–40% of all cases harboring TP53 defects and 6–5% of all cases of CLL [34,35]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.